Our study corroborates the assumption that it is necessary to analyze IUGR through a sex‐specific lens.[9a] Finally, APOA4 had been identified as a new biomarker and therapeutic target for IUGR in males, because it mitigates TG deposition in the context of hypoxia‐induced hepatocellular damage through the PPAR signaling pathway. This evidence concerns the gene APOA4 and fetal growth restriction.